PRESS RELEASE
Positive multi-center COPD trial with inhaled Bimosiamose to be
presented at the European Respiratory Society Annual Congress
2011 in Amsterdam
BERLIN/Hennigsdorf (Germany), September 21, 2011 - Revotar Biopharmaceuticals AG
recently announced that it successfully completed a multi-center Phase II trial to evaluate the
safety and efficacy of inhaled Bimosiamose for the treatment of patients with chronic
obstructive pulmonary disease (COPD).
Data have been accepted for the late breaking news session at the upcoming annual congress
of the European Respiratory Society (ERS) in Amsterdam and will be presented by the research
group of Prof. Helgo Magnussen in an oral presentation Tuesday, September 27th during
Session 460 (14:45-16:45, Forum).
As previously released, inhalation of Bimosiamose for 28 days on top of standard
bronchodilators was safe and well tolerated in 77 patients with moderate to severe COPD
(GOLD II-III). It led to a broad and significant attenuation of airway inflammation and trend
towards lung function improvements.
“Our data with Bimosiamose demonstrate a significant step forward in the anti-inflammatory
treatment of COPD”, said Prof. Wolfgang Meyer-Sabellek, CMO of Revotar. “We will discuss
future clinical development of our first in class inhaled drug with international key opinion
leaders in Amsterdam at one of the biggest and renowned respiratory conferences worldwide.”
"We are encouraged that our data are appreciated by the scientific community as a major
milestone on the way towards the establishment of pan-selectin antagonism as a novel
therapeutic option in COPD", added Dr. Martin Pöhlchen, CEO of Revotar.
About COPD
Chronic Obstructive Pulmonary Disease (COPD) comprises several serious conditions affecting
the lung. According to the WHO, estimated 64 million people have COPD worldwide in 2004.
More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths
globally. The WHO predicts that COPD will become the third leading cause of death worldwide
by 2030. In 2010, the global COPD market recorded sales of approximately 11 billion US-$.
There is a high unmet medical need in drugs modifying the underlying inflammation in COPD.
About Revotar Biopharmaceutical AG
Revotar develops innovative drugs for inflammatory indications such as chronic obstructive
pulmonary disease (COPD), acute lung injury (ALI) and asthma. Its lead candidate
Bimosiamose, a pan-selectin antagonist, has already passed several clinical phase I and phase
IIa trials in COPD, asthma, and psoriasis with a good safety and efficacy profile in over 300
patients and volunteers. Furthermore Revotar has two preclinical programs addressing
respiratory and other inflammatory diseases.
Contact Address:
Dr Martin Pöhlchen, CEO
Revotar Biopharmaceuticals AG
Neuendorfstr. 24a
D-16761 Hennigsdorf / Germany
Phone: +49-3302-2025010
Fax: +49-3302-2025030
Email:
info@revotar.com
www.revotar.com